Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects

Next Previous
Trial Profile

A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir; Raltegravir
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms SPRING-2
  • Sponsors ViiV Healthcare

Most Recent Events

  • 08 Oct 2020 Results of pooled analysis assessing the efficacy and safety profile of the integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) relative to comparator ART in PLWH naive to ART by age group from four phase III/IIIb, presented at the 15th International Congress on Drug Therapy and HIV Infection
  • 22 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
  • 22 Jul 2015 Pooled subgroup analysis, results presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top